8-K filing — STANDARD BIOTOOLS INC. (LAB)
Filed: 2026-08-05 AccNo: 0001193125-26-335106 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Standard BioTools Q2 EPS $(0.07) Misses $(0.03) Estimate, Sales $20.104M Miss $20.805M Estimate
Standard BioTools (NASDAQ:LAB) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.03) by 133.33 percent. This is a 22.22 percent increase over losses of $(0.09) per share
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Standard BioTools Receives $30M Illumina Earnout And Royalty Buyout; Agrees To Sell Mass Cytometry Business For Up To $10M Ahead Of Treeline Merger
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AstroNova, Inc. (Nasdaq – ALOT), Open Lending Corporation (Nasdaq – LPRO), Huntsman Corporation (NYSE – HUN), Standard BioTools Inc. (Nasdaq – LAB)
Brodsky & Smith law firm is investigating four merger transactions to determine whether company boards breached fiduciary duties to shareholders. The investigations concern AstroNova (being acquired by Arcline for $29.00/share), Open Lending (being acquired by ANV Group for $3.15/share), Huntsman (merging with Olin in a stock exchange), and Standard BioTools (being acquired by Treeline Biosciences). The firm is seeking shareholders to discuss whether fair processes were conducted and fair value provided.